价格

Alaunos Therapeutics

ACTIVE

2617 Bissonnet St Ste 225, Houston, Texas, 美国www.alaunos.comPublic1–10 名员工0亿美元

别名:

tcrt

tcrt-us

alaunos therapeutics, inc.

alaunos

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

概览

试验阶段分布

阶段

试验数

占比

1 期

73.0%

2 期

16.2%

3 期

5.4%

试验状态分布

已完成

46.0%

暂停

2.7%

终止

16.2%

Unknown

32.4%

撤回

2.7%

药物批准

暂无批准数据

资讯

Alaunos Therapeutics Reports Promising Preclinical Data for Non-Hormonal Obesity Drug ALN1003

- Alaunos Therapeutics announced positive preclinical results for ALN1003, showing up to 12.9% body weight reduction in diet-induced obesity mouse models. - The oral small-molecule drug demonstrated significant liver weight reductions of up to 55% and improvements in liver injury biomarkers compared to controls. - ALN1003 offers a differentiated non-hormonal approach to obesity treatment, potentially providing an alternative to current hormone-based therapies like GLP-1 drugs. - The company plans to advance toward IND-enabling studies while optimizing formulations and manufacturing processes with current cash runway extending into Q2 2026.

Mar 2, 2026

返回机构列表

Alaunos Therapeutics

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（37）

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

药物批准

资讯

Alaunos Therapeutics Reports Promising Preclinical Data for Non-Hormonal Obesity Drug ALN1003